<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01082445</url>
  </required_header>
  <id_info>
    <org_study_id>NACPIEDE</org_study_id>
    <nct_id>NCT01082445</nct_id>
  </id_info>
  <brief_title>Effects of N-acetylcysteine on Diabetic Foot Oxygenation</brief_title>
  <official_title>Effects of Prolonged N-acetylcysteine Administration on Foot Ulcer Oxygenation in Diabetic Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Turin, Italy</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Turin, Italy</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether N-acetylcysteine is effective in the
      treatment or prevention of the foot ulcers in diabetic patients.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2009</start_date>
  <completion_date type="Actual">November 2010</completion_date>
  <primary_completion_date type="Actual">November 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Tissue oxygenation improvement</measure>
    <time_frame>Basal (time 0) and after 3 months of treatment/observation</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Improvement of the endothelial function</measure>
    <time_frame>Basal (time 0) and after 3 months of treatment/observation</time_frame>
    <description>nitrites/nitrates - ICAM - VCAM - PAI-1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oxidation status reduction</measure>
    <time_frame>Basal (time 0) and after 3 months of treatment/observation</time_frame>
    <description>8-iso PGF-2alpha assessment</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">100</enrollment>
  <condition>Foot Ulcer, Diabetic</condition>
  <arm_group>
    <arm_group_label>N-acetylcysteine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>50 patients that receive 600 mg of acetylcysteine for 3 times a day.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>50 subjects taking placebo pills 3 times a day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>N-acetylcysteine</intervention_name>
    <description>600 mg, 1 tablet 3 times a day for 3 months</description>
    <arm_group_label>N-acetylcysteine</arm_group_label>
    <other_name>Fluimucil (R) 600 mg, tablets</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age between 45 and 70 years.

          -  Type 1 or 2 diabetes mellitus with foot ulcer (grade 0 stage C according to Texas
             University Classification).

          -  Written informed consent.

        Exclusion Criteria:

          -  N-acetylcysteine assumption in the 6 months previous to the study.

          -  Hypersensibility to acetylcysteine.

          -  Neoplasms, severe systemic, hepatic, pulmonary, cardiovascular or renal diseases.

          -  Psychiatric diseases or drug abuse problems.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Valentino Martina, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Turin, Italy</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Div. Endocrinology, Diabetology and Metabolism - University of Turin</name>
      <address>
        <city>Turin</city>
        <state>TO</state>
        <zip>10126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <link>
    <url>http://www.iwgdf.org/</url>
    <description>International Working Group on the Diabetic Foot</description>
  </link>
  <reference>
    <citation>Martina V, Masha A, Gigliardi VR, Brocato L, Manzato E, Berchio A, Massarenti P, Settanni F, Della Casa L, Bergamini S, Iannone A. Long-term N-acetylcysteine and L-arginine administration reduces endothelial activation and systolic blood pressure in hypertensive patients with type 2 diabetes. Diabetes Care. 2008 May;31(5):940-4. doi: 10.2337/dc07-2251. Epub 2008 Feb 11.</citation>
    <PMID>18268065</PMID>
  </reference>
  <reference>
    <citation>Masha A, Brocato L, Dinatale S, Mascia C, Biasi F, Martina V. N-acetylcysteine is able to reduce the oxidation status and the endothelial activation after a high-glucose content meal in patients with Type 2 diabetes mellitus. J Endocrinol Invest. 2009 Apr;32(4):352-6.</citation>
    <PMID>19636205</PMID>
  </reference>
  <reference>
    <citation>Martina V, Bruno GA, Zumpano E, Origlia C, Quaranta L, Pescarmona GP. Administration of glutathione in patients with type 2 diabetes mellitus increases the platelet constitutive nitric oxide synthase activity and reduces PAI-1. J Endocrinol Invest. 2001 Jan;24(1):37-41.</citation>
    <PMID>11227730</PMID>
  </reference>
  <reference>
    <citation>Ignarro LJ, Edwards JC, Gruetter DY, Barry BK, Gruetter CA. Possible involvement of S-nitrosothiols in the activation of guanylate cyclase by nitroso compounds. FEBS Lett. 1980 Feb 11;110(2):275-8.</citation>
    <PMID>6102928</PMID>
  </reference>
  <verification_date>March 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 4, 2010</study_first_submitted>
  <study_first_submitted_qc>March 5, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 8, 2010</study_first_posted>
  <last_update_submitted>March 7, 2012</last_update_submitted>
  <last_update_submitted_qc>March 7, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 8, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Turin, Italy</investigator_affiliation>
    <investigator_full_name>Valentino Martina</investigator_full_name>
    <investigator_title>Aggregated Professor</investigator_title>
  </responsible_party>
  <keyword>stage C</keyword>
  <keyword>grade 0 (Texas University)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Foot Ulcer</mesh_term>
    <mesh_term>Diabetic Foot</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acetylcysteine</mesh_term>
    <mesh_term>N-monoacetylcystine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

